CTM

Menu

Publication

PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia

par

Equipe GAD Aymeric Masson,1 Julien Paccaud,1 Martina Orefice,2 Estelle Colin,1 Outi Mäkitie,3 Valérie Cormier-Daire,4 Raissa Relator,5 Sourav Ghosh,5 Jean-Marc Strub,6 Christine Schaeffer-Reiss,6 Carlo Marcelis,7 David A. Koolen,7 Rolph Pfundt,8 Elke de Boer,7 Lisenka E.L.M. Vissers,7 Thatjana Gardeitchik,8 Lonneke A.M. Aarts,9 Tuula Rinne,7 Paulien A. Terhal,10 Nienke E. Verbeek,10 Linda C. Zuurbier,11 Astrid S. Plomp,12 Marja … Lire la suite

Proteogenomic characterization of bladder cancer reveals sensitivity to TRAIL-induced apoptosis in FGFR3-mutated tumors.

par

Equipe DesCarTes Groeneveld CS, Sanchez-Quiles V, Dufour F, Shi M, Dingli F, Nicolle R, Chapeaublanc E, Poullet P, Jeffery D, Krucker C, Maillé P, Vacherot F, Vordos D, Benhamou S, Lebret T, Micheau O, Zinovyev A, Loew D, Allory Y, de Reyniès A, Bernard-Pierrot I, Radvanyi F. European Urology 2024, May;85(5):483-494. Background Molecular understanding of … Lire la suite

TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling

par

Equipe DesCarTes Guerrache A & Micheau O Cells 2024, 13(6), 521; https://doi.org/10.3390/cells13060521 TNF-related apoptosis-inducing ligand (TRAIL or Apo2 or TNFSF10) belongs to the TNF superfamily. When bound to its agonistic receptors, TRAIL can induce apoptosis in tumour cells, while sparing healthy cells. Over the last three decades, this tumour selectivity has prompted many studies aiming at evaluating the … Lire la suite

Development of an Immuno-SPECT/Fluorescent Bimodal Tracer Targeting Human or Murine PD-L1 on Preclinical Models

par

Privat M, Massot A, Hermetet F, Al Sabea H, Racoeur C, Mabrouk N, Cordonnier M, Moreau M, Collin B, Bettaieb A, Denat F, Bodio E, Bellaye PS, Goze C, Paul C. Development of an Immuno-SPECT/Fluorescent Bimodal Tracer Targeting Human or Murine PD-L1 on Preclinical Models. J Med Chem. 2024 Jan 25. doi: 10.1021/acs.jmedchem.3c02120. Epub ahead … Lire la suite

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

par

Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C. A phase I … Lire la suite

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

par

Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F. First-line durvalumab and tremelimumab with … Lire la suite